Preclinical studies have shown that stabilization of HIF-1α leads to improved intestinal barrier functions (31), and gut-targeted HIF-1α stabilizers like GB004 may be a promising therapeutic approach for ulcerative colitis patients (32). Here, HIF1A is linked to ulcerative colitis.